Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Amneal Pharmaceuticals, Inc. Class A Common Stock stock (AMRX) is currently trading at $12.07. Amneal Pharmaceuticals, Inc. Class A Common Stock PE ratio is 53.77. Amneal Pharmaceuticals, Inc. Class A Common Stock PS ratio (Price-to-Sales) is 1.23. Analyst consensus price target for AMRX is $16.80. WallStSmart rates AMRX as Underperform.
- AMRX PE ratio analysis and historical PE chart
- AMRX PS ratio (Price-to-Sales) history and trend
- AMRX intrinsic value — DCF, Graham Number, EPV models
- AMRX stock price prediction 2025 2026 2027 2028 2029 2030
- AMRX fair value vs current price
- AMRX insider transactions and insider buying
- Is AMRX undervalued or overvalued?
- Amneal Pharmaceuticals, Inc. Class A Common Stock financial analysis — revenue, earnings, cash flow
- AMRX Piotroski F-Score and Altman Z-Score
- AMRX analyst price target and Smart Rating
Amneal Pharmaceuticals, Inc.
📊 No data available
Try selecting a different time range
AMRX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
AMRX trades 43% above its Graham fair value of $10.30, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, eps growth, institutional own.. Concerns around return on equity and price/book. Mixed signals suggest waiting for clearer direction before acting.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Key Strengths (4)
Earnings per share surging 261.00% year-over-year
Paying $1.23 for every $1 of annual revenue
50.17% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 86.1x book value
Very thin margins, barely profitable
Thin operating margins with cost pressures present
Solid revenue growth at 11.50% per year
Supporting Valuation Data
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Detailed Analysis Report
Overall Assessment
This company scores 46/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 4 register as strengths (avg 8.3/10) while 5 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (1.23) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 261.00%.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Profit Margin. Some valuation metrics including Price/Book (86.10) suggest expensive pricing. Growth concerns include Revenue Growth at 11.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -881.00%, Operating Margin at 14.10%, Profit Margin at 2.39%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -881.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 11.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AMRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AMRX's Price-to-Sales ratio of 1.23x trades at a deep discount to its historical average of 3.83x (54th percentile). The current valuation is 94% below its historical high of 19.83x set in Apr 2015, and 517% above its historical low of 0.2x in Mar 2023. Over the past 12 months, the PS ratio has expanded from ~0.9x, reflecting growing market expectations outpacing revenue growth.
Compare AMRX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Amneal Pharmaceuticals, Inc. Class A Common Stock is a mature, profitable business with steady cash generation. Revenue reached 3.0B with 12% growth year-over-year. Profit margins are strong at 239.0%, reflecting pricing power and operational efficiency.
Key Findings
Generating 87M in free cash flow and 130M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Valuation compression risk at a P/E of 53.8x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Amneal Pharmaceuticals, Inc. Class A Common Stock.
Bottom Line
Amneal Pharmaceuticals, Inc. Class A Common Stock is a well-established business delivering consistent profitability with 239.0% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(90 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:24:16 AM
About Amneal Pharmaceuticals, Inc. Class A Common Stock(AMRX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.